ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

bizrolertinib

Also written as “ZN-A-1041”, “ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b” and “ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b”.

Its studies are mostly in Breast Neoplasms, led by 2 companies.

Drug pageBizrolertinib: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Feb 10, 20265 company-led studies, 2 open or runningNext primary completion: Aug 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only42 open or runningphase 3since Feb 10, 2026Oct 17, 2022Aug 31, 2027phase 2 · NCT05593094
Suzhou Zanrong Pharma10 open or runningphase 1since Jul 10, 2020Jul 10, 2020none ahead
  • Named in Hoffmann-La Roche’s own pipeline as RG6596 bizrolertinib, phase 2, as of Oct 22, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Suzhou Zanrong Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 10, 2020First study: phase 1 study in Brain NeoplasmsFirst studyNCT04487236 · 61 enrolled · China

TargetBeta

“An orally bioavailable inhibitor of the receptor tyrosine kinase human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential antineoplastic activity. Upon oral administration, bizrolertinib selectively binds to and inhibits the activity of HER2. This prevents HER2-mediated signa…”NCIt, read by Claude
“An orally bioavailable inhibitor of the receptor tyrosine kinase human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), ”NCIt, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

The one study Suzhou Zanrong Pharma leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04487236Brain Neoplasms · China1CompletedApr 16, 202461

How it is read

Names in the registry

  • “ZN-A-1041”, 2 entries
  • “ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b”, 1 entry
  • “ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b”, 1 entry
  • “ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b”, 1 entry
  • “ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1c”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.